Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
4.000
+0.170 (4.44%)
At close: Oct 20, 2025, 4:00 PM EDT
4.010
+0.010 (0.25%)
Pre-market: Oct 21, 2025, 7:49 AM EDT

Company Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.

Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis.

The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Altimmune, Inc.
Altimmune logo
CountryUnited States
Founded1997
IndustryBiotechnology
SectorHealthcare
Employees59
CEOVipin Garg

Contact Details

Address:
910 Clopper Road, Suite 201S
Gaithersburg, Maryland 20878
United States
Phone240 654 1450
Websitealtimmune.com

Stock Details

Ticker SymbolALT
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001326190
CUSIP Number02155H200
ISIN NumberUS02155H2004
Employer ID20-2726770
SIC Code2834

Key Executives

NamePosition
Dr. Vipin K. Garg Ph.D.President, Chief Executive Officer and Director
Dr. M. Scot Roberts Ph.D.Chief Scientific Officer
Gregory L. Weaver CPA, M.B.A.Chief Financial Officer
Andrew Shutterly M.S.Principal Financial and Accounting Officer and Corporate Controller
Bertrand Georges Ph.D.Chief Technology Officer
Tony Blandin B.S.Vice President of Quality and Compliance Management
Robin E. Abrams J.D.General Counsel
Raymond M. Jordt M.B.A.Chief Business Officer
Linda M. RichardsonChief Commercial Officer
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Oct 3, 20258-KCurrent Report
Sep 25, 20258-KCurrent Report
Aug 19, 2025UPLOADFiling
Aug 15, 2025ARSFiling
Aug 15, 2025DEF 14AOther definitive proxy statements
Aug 12, 202510-QQuarterly Report
Aug 12, 20258-KCurrent Report
Aug 8, 2025UPLOADFiling
Jul 16, 2025SCHEDULE 13G/AFiling
Jun 26, 20258-KCurrent Report